Speaker(s): 

Megan Roberts, PhD- Associate Professor and Interim Vice Chair, Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill

Disclosures:

1. Thermo Fisher Scientific ["Spouse holds stock"]

2. Merck ["Spouse holds stock", "Consultant/Advisor"]

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Describe need for implementation science research in population genetic screening.
2. Describe common barriers for PGS programs during the pre-adoption phase.
3. Describe how implementation mapping can be used to develop responsive strategies for PGS adoption.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Juliann Savatt, MS, LCGC, Melissa Kelly, MS, LCGC, Marc Williams, MD, and Cara McCormick, MPH have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None